Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dalcotidine SCHEMBL29395522 | 1.00 | HRH2 (0.70) | HRH2HRH3 | |
| SCHEMBL10672985 | 0.96 | HRH2 (0.67) | HRH2HRH3 | |
| SCHEMBL9513497 | 0.90 | HRH2 (0.71) | HRH2HRH3 | |
| SCHEMBL10675639 | 0.89 | HRH2 (0.62) | HRH2HRH3 | |
| SCHEMBL10668657 | 0.89 | HRH2 (0.62) | HRH2HRH3 | |
| SCHEMBL11382800 | 0.88 | HRH2 (0.77) | HRH2HRH3 | |
| SCHEMBL10668494 | 0.88 | — | — | |
| SCHEMBL9572472 | 0.88 | HRH2 (0.77) | HRH2HRH3 | |
| SCHEMBL10673022 | 0.87 | HRH2 (0.67) | HRH2HRH3 | |
| SCHEMBL10838806 | 0.86 | HRH2 (0.75) | HRH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| US-20230349922-A1 | H2 Blockers Targeting Liver Macrophages for the Prevention and Treatment of Liver Disease and Cancer | UNIVERSITÉ DE STRASBOURG (FR) | 2023-11-02 | — | — | US | claimed |
| EP-4196793-A1 | H2 BLOCKERS TARGETING LIVER MACROPHAGES FOR THE PREVENTION AND TREATMENT OF LIVER DISEASE AND CANCER | Université de Strasbourg (FR) | 2023-06-21 | — | — | EP | claimed |
| WO-2022034121-A1 | H2 BLOCKERS TARGETING LIVER MACROPHAGES FOR THE PREVENTION AND TREATMENT OF LIVER DISEASE AND CANCER | UNIVERSITÉ DE STRASBOURG (FR) | 2022-02-17 | — | — | WO | claimed |
| WO-2015169957-A1 | PHARMACEUTICAL COMBINATIONS OF RIVAROXABAN AND H2-RECEPTOR ANTAGONISTS | SANOVEL ILAC SANAYI VE TICARET A.S. (TR) | 2015-11-12 | — | — | WO | claimed |
| EP-2942058-A1 | Pharmaceutical combinations of rivaroxaban and H2-receptor antagonists | Sanovel Ilac Sanayi ve Ticaret A.S. (TR) | 2015-11-11 | — | — | EP | claimed |
| WO-2015155297-A1 | PHARMACEUTICAL COMBINATIONS OF DABIGATRAN AND H2-RECEPTOR ANTAGONISTS | SANOVEL ILAC SANAYI VE TICARET A.S. (TR) | 2015-10-15 | — | — | WO | claimed |
| EP-2929884-A1 | PHARMACEUTICAL COMBINATIONS OF DABIGATRAN AND H2-RECEPTOR ANTAGONISTS | Sanovel Ilac Sanayi ve Ticaret A.S. (TR) | 2015-10-14 | — | — | EP | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| EP-0454449-A1 | Carboxylic acid derivatives | GLAXO GROUP LIMITED (GB) | 1991-10-30 | — | — | EP | claimed |
| JP-5086014-A | — | — | None | — | — | JP | disclosed |
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | disclosed |
| US-4952591-A | HISTAMINE H2-ANTAGONISTS | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1990-08-28 | — | — | US | disclosed |
| EP-0302422-A2 | Urea derivatives | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1989-02-08 | — | — | EP | disclosed |